Drug Search Results
More Filters [+]

Paromomycin

Alternative Names: paromomycin, humatin
Latest Update: 2024-04-08
Latest Update Note: Clinical Trial Update

Product Description

Paromomycin is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. It is out of use as an antibiotic but was licensed in 2007 in India as an effective, well tolerated and affordable treatment for visceral leishmaniasis (VL) at a dose of 11 mg/kg (base) for 21 days.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18947845/)

Mechanisms of Action: Protein Synthesis Inhibitor,30S Ribosomal Subunit Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Intramuscular

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Canada | Colombia | Dominican Republic | Germany | Greece | India | Indonesia | Israel | Italy | Japan | Luxembourg | Malta | Poland | Slovenia | South Africa | Spain | Switzerland | United Kingdom | United States | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Paromomycin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title